Portage Biotech Inc Ord (PRTG)

$8.00 -0.47 (-5.55%)
Market Cap 8.88M
Revenue (ttm) 0.00
Net Income (ttm) -6.77M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 27,500
Avg Vol 116,114
Day's Range N/A - N/A
Shares Out 1.05M
Stochastic %K 16%
Beta 0.24
Analysts Hold
Price Target $140.00

Company Profile

Portage Biotech Inc., a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline comprises PORT-3, a polylactide-co-glycolide, which is in phase 1 to treat NY-ESO-1 positive tumors; PORT-6, a highly selective A2A receptor antagonist, which is in phase 1a for the treatment of solid tumors; PORT-8, a dual inhibitor of adenosine receptors 2A and 2B, which is in preclinical trial to treat solid tumors; PORT-9, an A2B...

Industry: Biotechnology
Sector: Healthcare
Phone: 302 219 5556
Address:
Clarence Thomas Building, P.O. Box 4649 Road Town, Tortola, British Virgin Islands
PurplePenguin
PurplePenguin Aug. 19 at 7:10 PM
$PRTG There's a scammer named Peter Molloy at Portage who is the CEO of a subsidiary of Portage and also founded another subsidiary at Portage. Peter was part of the Taronis Tech scam and moved to portage with a Taronis-owned subsidiary named Tarus. Usually when there's a scammer like Peter who is so closely knit to a company such as Peter is to Portage Biotech, it indicates that the whole company is also corrupt. If you're a shareholder, keep a close eye for any shady business.
0 · Reply
yft212
yft212 Aug. 18 at 6:27 PM
$SNGX $PRTG Both have very high borrow rates.
0 · Reply
Stopcapping
Stopcapping Aug. 13 at 12:24 PM
$PRTG This will push to 15 soon.End of week always possible.Just need that good news on humans.We get that we hurdle!!
0 · Reply
JoseGilberto109
JoseGilberto109 Aug. 8 at 11:25 PM
Wow what is happening to SNSE right now!? Seems like ALL volume and momentum are shifting into SNSE!! Could it be the next crazy runner of the day?? Only 500k float on SNSE - Bulls should keep it on watch!! Also watching: $MRM $PAPL $BTAI $PRTG !!!
0 · Reply
Drewbenson877
Drewbenson877 Aug. 8 at 12:49 PM
$PRTG 11
0 · Reply
Stopcapping
Stopcapping Aug. 8 at 12:25 PM
$PRTG Looking for positive news on trials.And compliance.Both will rocket this.Let wait and see.
1 · Reply
HectorNumba9
HectorNumba9 Aug. 8 at 10:34 AM
$PRTG you'll learn your listen just a dead bounce til the real news comes. $15ISH tops then back then til then
0 · Reply
Getrichordietrying617
Getrichordietrying617 Aug. 7 at 6:38 PM
$PRTG shits wild I can’t get a live price everything is delayed for this ticker on stock twits, yahoo and some other platforms wtf is going on Charles Shwabb seems to be working occasionally it’s only this ticker
1 · Reply
Starwarsjedi
Starwarsjedi Aug. 7 at 6:33 PM
$PRTG what a special about this company pipeline
1 · Reply
Pitts123
Pitts123 Aug. 7 at 4:20 PM
$PRTG No red candles at all on stock Twits chart
0 · Reply
Latest News on PRTG
Portage Biotech Reports Results for Fiscal Year Ended March 31, 2025

Jul 25, 2025, 4:15 PM EDT - 25 days ago

Portage Biotech Reports Results for Fiscal Year Ended March 31, 2025

Portage Biotech Regains Full Compliance with Nasdaq Continued Listing Requirements

Jun 25, 2025, 7:00 AM EDT - 7 weeks ago

Portage Biotech Regains Full Compliance with Nasdaq Continued Listing Requirements

Portage Biotech and Compedica Stock-for-Stock Exchange

Jun 9, 2025, 6:00 AM EDT - 2 months ago

Portage Biotech and Compedica Stock-for-Stock Exchange

Portage Biotech Stock Surges As It Prepares For Human Trial

Apr 28, 2025, 10:37 AM EDT - 4 months ago

Portage Biotech Stock Surges As It Prepares For Human Trial

Portage Biotech Reports Confirmatory Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7

Apr 28, 2025, 6:00 AM EDT - 4 months ago

Portage Biotech Reports Confirmatory Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7

Why Is Portage Biotech Stock Skyrocketing Friday?

Mar 28, 2025, 1:13 PM EDT - 5 months ago

Why Is Portage Biotech Stock Skyrocketing Friday?

Portage Biotech Shares More Than Double After Results of PORT-7 Tumor Treatment Trial

Mar 27, 2025, 6:02 PM EDT - 5 months ago

Portage Biotech Shares More Than Double After Results of PORT-7 Tumor Treatment Trial

Portage Biotech Resumes Enrollment in Final Cohort of Dose Escalation for Port-6 in ADPORT-601 Trial

Mar 12, 2025, 8:00 AM EDT - 5 months ago

Portage Biotech Resumes Enrollment in Final Cohort of Dose Escalation for Port-6 in ADPORT-601 Trial

Portage Biotech Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing Requirements

Feb 12, 2025, 4:15 PM EST - 6 months ago

Portage Biotech Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing Requirements

Portage Biotech Announces Completion of $2.15 Million Private Financing

Jan 30, 2025, 4:30 PM EST - 7 months ago

Portage Biotech Announces Completion of $2.15 Million Private Financing

Portage Biotech Announce Re-Launch of Adenosine Subsidiary as Independently Managed Company; Appointment of Peter Molloy to Lead New Company

Jan 6, 2025, 5:00 AM EST - 8 months ago

Portage Biotech Announce Re-Launch of Adenosine Subsidiary as Independently Managed Company; Appointment of Peter Molloy to Lead New Company

Portage Biotech Announces Receipt of Nasdaq Noncompliance Letter

Dec 12, 2024, 4:15 PM EST - 8 months ago

Portage Biotech Announces Receipt of Nasdaq Noncompliance Letter

Portage Biotech Reports Results for Fiscal Quarter Ended September 30, 2024

Nov 26, 2024, 4:05 PM EST - 9 months ago

Portage Biotech Reports Results for Fiscal Quarter Ended September 30, 2024

Portage Biotech Announces Plans to Expand its Evaluation of Strategic Alternatives

Apr 12, 2024, 8:01 AM EDT - 1 year ago

Portage Biotech Announces Plans to Expand its Evaluation of Strategic Alternatives

Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) shares

Mar 26, 2024, 8:01 AM EDT - 1 year ago

Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) shares

Portage Biotech Reports Results for Fiscal Quarter Ended December 31, 2023, and Business Update

Feb 28, 2024, 5:10 PM EST - 1 year ago

Portage Biotech Reports Results for Fiscal Quarter Ended December 31, 2023, and Business Update

Portage Biotech Reports Business and Strategic Update

Jan 4, 2024, 8:00 AM EST - 1 year ago

Portage Biotech Reports Business and Strategic Update

Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2023, and Business Update

Nov 28, 2023, 4:01 PM EST - 1 year ago

Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2023, and Business Update

Portage Biotech Presents Updates on its iNKT and Adenosine programs at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

Nov 6, 2023, 8:01 AM EST - 1 year ago

Portage Biotech Presents Updates on its iNKT and Adenosine programs at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

Portage Biotech Announces $6.0 Million Registered Direct Offering

Sep 29, 2023, 8:00 AM EDT - 2 years ago

Portage Biotech Announces $6.0 Million Registered Direct Offering

Portage Biotech to Participate in Panel Discussion at the Cantor Global Healthcare Conference

Sep 20, 2023, 8:00 AM EDT - 2 years ago

Portage Biotech to Participate in Panel Discussion at the Cantor Global Healthcare Conference

Portage Biotech Announces Collaboration with Merck to Evaluate Two Next-Generation Adenosine Antagonists in Combination with KEYTRUDA® (Pembrolizumab) in Solid Tumors

Sep 5, 2023, 8:00 AM EDT - 2 years ago

Portage Biotech Announces Collaboration with Merck to Evaluate Two Next-Generation Adenosine Antagonists in Combination with KEYTRUDA® (Pembrolizumab) in Solid Tumors

Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2023 and Business Update

Aug 30, 2023, 8:00 AM EDT - 2 years ago

Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2023 and Business Update

Portage Biotech Reports Fiscal Year-Ended March 31, 2023 Financial Results and Business Update

Jul 31, 2023, 4:05 PM EDT - 2 years ago

Portage Biotech Reports Fiscal Year-Ended March 31, 2023 Financial Results and Business Update

Portage Biotech Announces First Patient Dosed in Phase 1a Trial of PORT-6 in Select Solid Tumors

Jun 26, 2023, 8:00 AM EDT - 2 years ago

Portage Biotech Announces First Patient Dosed in Phase 1a Trial of PORT-6 in Select Solid Tumors

Portage Biotech Reports Updated Interim Data for Lead iNKT Engager, PORT-2, in a Phase 1/2 Trial for the Treatment of Advanced Melanoma and Metastatic Non-Small Cell Lung Cancer at the 2023 American Society for Clinical Oncology (ASCO) Annual Meeting

Jun 5, 2023, 8:00 AM EDT - 2 years ago

Portage Biotech Reports Updated Interim Data for Lead iNKT Engager, PORT-2, in a Phase 1/2 Trial for the Treatment of Advanced Melanoma and Metastatic Non-Small Cell Lung Cancer at the 2023 American Society for Clinical Oncology (ASCO) Annual Meeting

Portage Biotech to Participate in Panel Discussion During the 2023 BIO International Conference

Jun 1, 2023, 8:00 AM EDT - 2 years ago

Portage Biotech to Participate in Panel Discussion During the 2023 BIO International Conference

Portage Biotech Announces Upcoming PORT-2 Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 26, 2023, 5:00 PM EDT - 2 years ago

Portage Biotech Announces Upcoming PORT-2 Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

Portage Biotech to Present at Oppenheimer's 33rd Annual Healthcare Conference

Mar 7, 2023, 8:00 AM EST - 2 years ago

Portage Biotech to Present at Oppenheimer's 33rd Annual Healthcare Conference

Portage Biotech Announces Results for Fiscal Quarter Ended December 31, 2022

Mar 1, 2023, 8:00 AM EST - 2 years ago

Portage Biotech Announces Results for Fiscal Quarter Ended December 31, 2022

Portage Biotech Hosting Key Opinion Leader Event on Targeting the Adenosine Pathway in Cancer

Feb 27, 2023, 4:05 PM EST - 2 years ago

Portage Biotech Hosting Key Opinion Leader Event on Targeting the Adenosine Pathway in Cancer

Portage Biotech to Participate in Citi's 2023 Virtual Oncology Leadership Summit

Feb 15, 2023, 8:00 AM EST - 2 years ago

Portage Biotech to Participate in Citi's 2023 Virtual Oncology Leadership Summit

Portage Biotech Announces Results for Fiscal Quarter Ended September 30, 2022

Nov 29, 2022, 4:43 PM EST - 2 years ago

Portage Biotech Announces Results for Fiscal Quarter Ended September 30, 2022

Portage Biotech Presents Updated Data on the Phase 1/2 Trial Evaluating PORT-2 at the Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting

Nov 10, 2022, 9:00 AM EST - 3 years ago

Portage Biotech Presents Updated Data on the Phase 1/2 Trial Evaluating PORT-2 at the Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting

Portage Biotech Announces Clinical Trial Collaboration Agreement with Merck

Nov 8, 2022, 8:00 AM EST - 3 years ago

Portage Biotech Announces Clinical Trial Collaboration Agreement with Merck

Portage Biotech Provides Research and Development Update

Sep 14, 2022, 8:39 AM EDT - 3 years ago

Portage Biotech Provides Research and Development Update

Portage Biotech to Present at Upcoming Investor Conferences

Sep 8, 2022, 8:00 AM EDT - 3 years ago

Portage Biotech to Present at Upcoming Investor Conferences

Portage Biotech Announces Results for Fiscal Quarter Ended June 30, 2022

Aug 29, 2022, 8:00 AM EDT - 3 years ago

Portage Biotech Announces Results for Fiscal Quarter Ended June 30, 2022

Portage Biotech Announces Leadership Updates

Aug 18, 2022, 8:00 AM EDT - 3 years ago

Portage Biotech Announces Leadership Updates

UPDATE -- Portage Biotech Announces Results for Fiscal Year Ended March 31, 2022

Aug 1, 2022, 9:10 AM EDT - 3 years ago

UPDATE -- Portage Biotech Announces Results for Fiscal Year Ended March 31, 2022

Portage Biotech Announces Results for Fiscal Year Ended March 31, 2022

Aug 1, 2022, 8:00 AM EDT - 3 years ago

Portage Biotech Announces Results for Fiscal Year Ended March 31, 2022

Portage Biotech Shares Gain On Buying Outstanding Minority Interest In iNKT Platform

Jul 20, 2022, 4:07 PM EDT - 3 years ago

Portage Biotech Shares Gain On Buying Outstanding Minority Interest In iNKT Platform

Portage Biotech Acquires Outstanding Minority Interest of Invariant Natural Killer T cell (iNKT) Agonist Platform

Jul 20, 2022, 9:00 AM EDT - 3 years ago

Portage Biotech Acquires Outstanding Minority Interest of Invariant Natural Killer T cell (iNKT) Agonist Platform

Portage Biotech Bolsters Pipeline with Acquisition of Four Candidates Targeting the Adenosine Pathway

Jul 6, 2022, 4:05 PM EDT - 3 years ago

Portage Biotech Bolsters Pipeline with Acquisition of Four Candidates Targeting the Adenosine Pathway

Portage Biotech Summarizes Data Presented at ASCO 2022 Annual Meeting Including Updates from Ongoing PORT-2 Study

Jun 6, 2022, 8:00 AM EDT - 3 years ago

Portage Biotech Summarizes Data Presented at ASCO 2022 Annual Meeting Including Updates from Ongoing PORT-2 Study

Portage Biotech Enters Cooperative Research and Development Agreement with U.S. National Cancer Institute and Stimunity

Apr 25, 2022, 8:00 AM EDT - 3 years ago

Portage Biotech Enters Cooperative Research and Development Agreement with U.S. National Cancer Institute and Stimunity

Portage Biotech Highlights Promising Data Presented on STING-Activating Therapy, PORT-5 (STI-001) at AACR 2022 Annual Meeting

Apr 13, 2022, 10:00 AM EDT - 3 years ago

Portage Biotech Highlights Promising Data Presented on STING-Activating Therapy, PORT-5 (STI-001) at AACR 2022 Annual Meeting

Portage Biotech Provides Update on Clinical-Stage and Development Programs

Mar 31, 2022, 8:00 AM EDT - 3 years ago

Portage Biotech Provides Update on Clinical-Stage and Development Programs

Portage Biotech Announces Presentation of PORT-5 (STI-001) Late-Breaking Data at AACR 2022 Annual Meeting

Mar 9, 2022, 9:00 AM EST - 3 years ago

Portage Biotech Announces Presentation of PORT-5 (STI-001) Late-Breaking Data at AACR 2022 Annual Meeting

Portage Biotech Announces Financial Results and Provides Business Update for Third Quarter of 2022 Fiscal Year

Feb 24, 2022, 5:43 PM EST - 3 years ago

Portage Biotech Announces Financial Results and Provides Business Update for Third Quarter of 2022 Fiscal Year

PurplePenguin
PurplePenguin Aug. 19 at 7:10 PM
$PRTG There's a scammer named Peter Molloy at Portage who is the CEO of a subsidiary of Portage and also founded another subsidiary at Portage. Peter was part of the Taronis Tech scam and moved to portage with a Taronis-owned subsidiary named Tarus. Usually when there's a scammer like Peter who is so closely knit to a company such as Peter is to Portage Biotech, it indicates that the whole company is also corrupt. If you're a shareholder, keep a close eye for any shady business.
0 · Reply
yft212
yft212 Aug. 18 at 6:27 PM
$SNGX $PRTG Both have very high borrow rates.
0 · Reply
Stopcapping
Stopcapping Aug. 13 at 12:24 PM
$PRTG This will push to 15 soon.End of week always possible.Just need that good news on humans.We get that we hurdle!!
0 · Reply
JoseGilberto109
JoseGilberto109 Aug. 8 at 11:25 PM
Wow what is happening to SNSE right now!? Seems like ALL volume and momentum are shifting into SNSE!! Could it be the next crazy runner of the day?? Only 500k float on SNSE - Bulls should keep it on watch!! Also watching: $MRM $PAPL $BTAI $PRTG !!!
0 · Reply
Drewbenson877
Drewbenson877 Aug. 8 at 12:49 PM
$PRTG 11
0 · Reply
Stopcapping
Stopcapping Aug. 8 at 12:25 PM
$PRTG Looking for positive news on trials.And compliance.Both will rocket this.Let wait and see.
1 · Reply
HectorNumba9
HectorNumba9 Aug. 8 at 10:34 AM
$PRTG you'll learn your listen just a dead bounce til the real news comes. $15ISH tops then back then til then
0 · Reply
Getrichordietrying617
Getrichordietrying617 Aug. 7 at 6:38 PM
$PRTG shits wild I can’t get a live price everything is delayed for this ticker on stock twits, yahoo and some other platforms wtf is going on Charles Shwabb seems to be working occasionally it’s only this ticker
1 · Reply
Starwarsjedi
Starwarsjedi Aug. 7 at 6:33 PM
$PRTG what a special about this company pipeline
1 · Reply
Pitts123
Pitts123 Aug. 7 at 4:20 PM
$PRTG No red candles at all on stock Twits chart
0 · Reply
Stopcapping
Stopcapping Aug. 7 at 3:42 PM
$PRTG News will come at 15.So they can push it to 45/50 area.When this hits 15 dollars news comes then rip!!!
1 · Reply
Stopcapping
Stopcapping Aug. 7 at 12:14 PM
$PRTG Slow and steady this is boom 💥 at some point.
0 · Reply
BestNwest
BestNwest Aug. 7 at 3:42 AM
$PRTG nice chart
0 · Reply
IBcurious
IBcurious Aug. 6 at 9:51 PM
$PRTG interesting movement
0 · Reply
Fixer00
Fixer00 Aug. 6 at 7:32 PM
$PRTG hope Merck is buying these shares.
0 · Reply
ChazzyTrades
ChazzyTrades Aug. 6 at 4:40 PM
$PRTG waiting for buy signal
2 · Reply
Stopcapping
Stopcapping Aug. 6 at 2:55 PM
$PRTG 👻
0 · Reply
Soyaz
Soyaz Aug. 6 at 1:36 PM
$PRTG 👀
0 · Reply
littlegretti
littlegretti Aug. 5 at 7:19 PM
$PRTG Could go AM. I didn’t see why it would top out at 7.15 but who knows
0 · Reply
littlegretti
littlegretti Aug. 5 at 6:09 PM
$PRTG I think it’s going to run soon. Looks like they tried stopping people out
0 · Reply
Drewbenson877
Drewbenson877 Aug. 5 at 3:58 PM
$PRTG
1 · Reply
littlegretti
littlegretti Aug. 5 at 3:17 PM
$PRTG Two ways I see this stock likes playing after a bounce. 1. Small pull back and then trickle slow down for days. Then the pop up or 2. It sits n waits till the pop up. Or 3. I am totally wrong lol.
1 · Reply